Trevi Therapeutics Inc TRVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
-
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
-
Trevi Therapeutics to Participate in September Investor and Medical Conferences
-
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
-
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
-
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Trading Information
- Previous Close Price
- $3.08
- Day Range
- $2.94–3.16
- 52-Week Range
- $0.97–4.00
- Bid/Ask
- $2.99 / $3.50
- Market Cap
- $228.66 Mil
- Volume/Avg
- 1.8 Mil / 285,707
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
Comparables
Valuation
|
Metric
|
TRVI
|
AVIR
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 18.22 |
Price/Book Value | 3.44 | 0.61 | 2.79 |
Price/Sales | — | — | 6.73 |
Price/Cash Flow | — | — | 14.42 |
Price/Earnings
TRVI
AVIR
UTHR
Financial Strength
|
Metric
|
TRVI
|
AVIR
|
UTHR
|
|---|---|---|---|
Quick Ratio | 10.29 | 18.87 | 3.92 |
Current Ratio | 10.68 | 19.02 | 4.35 |
Interest Coverage | −4,780.89 | — | 22.67 |
Quick Ratio
TRVI
AVIR
UTHR
Profitability
|
Metric
|
TRVI
|
AVIR
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −40.88% | −23.62% | 16.95% |
Return on Equity (Normalized) | −44.19% | −25.11% | 20.53% |
Return on Invested Capital (Normalized) | −48.62% | −29.21% | 16.62% |
Return on Assets
TRVI
AVIR
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mswgwlpjp | Jfhf | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Drgpnxfg | Xlvcmp | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zbswmfcx | Jbymf | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dmlxhvmz | Mtmng | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Hgwtznjn | Qnqc | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Bzvlbjky | Tspgv | $28.0 Bil | |||
| Moderna Inc
MRNA
| Bcrwptpx | Qwsx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Qkyntttb | Dvgy | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mtmyvqc | Xbbfvt | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Qpbslpbv | Qgvcdg | $12.6 Bil |
United States